# Dupilumab in Eosinophilic Gastritis

> **NCT03678545** · PHASE2 · COMPLETED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 41 (actual)

## Conditions studied

- Eosinophilic Gastritis
- Eosinophilic Gastroenteritis

## Interventions

- **DRUG:** Dupilumab (blinded)
- **DRUG:** Placebo (blinded)

## Key facts

- **NCT ID:** NCT03678545
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-15
- **Primary completion:** 2024-03-04
- **Final completion:** 2024-11-13
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-11-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03678545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03678545, "Dupilumab in Eosinophilic Gastritis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03678545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*